Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Income (2016 - 2025)

Guided Therapeutics' Operating Income history spans 15 years, with the latest figure at -$485000.0 for Q3 2025.

  • For Q3 2025, Operating Income rose 13.55% year-over-year to -$485000.0; the TTM value through Sep 2025 reached -$2.2 million, down 6.55%, while the annual FY2024 figure was -$2.1 million, 39.02% up from the prior year.
  • Operating Income for Q3 2025 was -$485000.0 at Guided Therapeutics, up from -$763000.0 in the prior quarter.
  • Across five years, Operating Income topped out at -$359000.0 in Q1 2024 and bottomed at -$1.5 million in Q2 2023.
  • The 5-year median for Operating Income is -$561000.0 (2021), against an average of -$680157.9.
  • The largest annual shift saw Operating Income crashed 254.9% in 2021 before it surged 57.41% in 2024.
  • A 5-year view of Operating Income shows it stood at -$435000.0 in 2021, then crashed by 117.93% to -$948000.0 in 2022, then skyrocketed by 48.84% to -$485000.0 in 2023, then dropped by 9.9% to -$533000.0 in 2024, then rose by 9.01% to -$485000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Operating Income are -$485000.0 (Q3 2025), -$763000.0 (Q2 2025), and -$414000.0 (Q1 2025).